Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

    Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

    Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

      Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

      Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

        Sanghamitra Saha headshot

        Biotech ETFs in Focus on String of Q2 Earnings Beat

        Biotech ETFs draw attention post impressive Q2 results.

          Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

          Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.

            Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat

            Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.

              Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

              Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.

                PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

                PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

                  Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well

                  Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

                    Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise

                    Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.

                      Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

                      Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.

                        Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates

                        Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.

                          AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss

                          AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.

                            Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2

                            Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.

                              VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y

                              VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.

                                Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus

                                Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.

                                  Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

                                  The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

                                    Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up

                                    Radius' (RDUS) Q2 results are encouraging as sales of its lead osteoporosis drug, Tymlos, continue to gain traction.

                                      Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat

                                      Alnylam (ALNY) posted wider-than-expected loss in the second quarter of 2018 and received a positive opinion from the CHMP for the marketing authorization of patisiran.

                                        Sheraz Mian headshot

                                        Q2 Scorecard & Research Reports for Gilead, American Tower & Others

                                        Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), American Tower (AMT) and Chubb (CB).

                                          Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2

                                          Ultragenyx posts narrower than expected loss and revenues beat estimates in the second quarter of 2018.

                                            Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks

                                            Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.

                                              bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss

                                              bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.

                                                Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

                                                Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.

                                                  Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers

                                                  Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.